Tag Archives: Drug Discovery Programmes

A Further Set-Back for Progress in Dementia Drug Development? (BBC News)

Posted on January 11, 2018 by Dementia and Elderly Care News

Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding | Leave a comment

Research Towards a World Without Dementia: Marking World Alzheimer’s Day / World Alzheimer’s Month 2017 (Alzheimer’s Disease International / Department of Health)

Posted on September 23, 2017 by Dementia and Elderly Care News

Summary Information is available from Alzheimer’s Disease International (ADI) concerning World Alzheimer’s Month (September) and World Alzheimer’s Day 2017, which was on September 21st 2017. The theme for this year’s World Alzheimer’s Month campaign is again “Remember Me”. The UK … Continue reading →

Posted in Charitable Bodies, Commissioning, Department of Health, Diagnosis, In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged 70th World Health Assembly Adopted Global Action Plan on Dementia, Ageing Population, Awareness, Awareness Campaigns, Awareness Raising, Carey Mulligan, Carey Mulligan: UK Global Dementia Friends Ambassador, Collaborative Research, Collaborative Working, Community and Voluntary Sector, Dementia Awareness Campaigns, Dementia Awareness Raising, Dementia Friends, Dementia Friends Programme, Dementia Research, Dementia Research Institute (DRI), Dementia-Friendly Communities, Dementia-Friendly Environments, Dementia-Friendly Organisations, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, First G8 Dementia Summit, Former Health Secretary Jeremy Hunt, G8 Dementia Summit, G8 Dementia Summit Declaration, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Global Action Plan on Dementia, Global Alzheimer’s and Dementia Action Alliance, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Context, Global Dementia Friends Ambassadors, Global Leadership, International Collaborations, International Dementia Research, Leadership for Compassionate Care, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Partnership Working, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Stigma of Dementia, Stigma-Free Environments, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Voluntary Organisations, WHO Global Action Plan on the Public Health Response to Dementia 2017-2025, World Alzheimer's Month 2017 (Remember Me), World Alzheimer’s Day 2017, World Alzheimer’s Month 2017, Yuichiro Miura: Japan’s Dementia Supporters Ambassador | Leave a comment

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Posted on April 20, 2017 by Dementia and Elderly Care News

Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →

Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans | Leave a comment

Future Director of the UK Dementia Research Institute (MRC / Guardian / JAMA Neurology)

Posted on December 14, 2016 by Dementia and Elderly Care News

Summary Professor Bart De Strooper has been appointed as the Director of the UK Dementia Research Institute (UK DRI). Prof. De Strooper currently leads the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and is scientific … Continue reading →

Posted in For Researchers (mostly), In the News, International, Models of Dementia Care, National, Quick Insights, UK, Universal Interest | Tagged Ageing Population, Belgium, Biomarker Development, Biomarkers, Biomarkers Research Programmes, Brain Imaging, Dementia and Alzheimer's Disease: Leading Cause of Death in 2015, Dementia Challenge 2020, Dementia Research, Dementia Research Careers, Dementia Research Institute (DRI), Dementia Research: Roadmap for the Next Decade, Department of Neuroscience: Mayo Clinic Florida, Diagnostic Imaging, Diagnostics, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Environmental Risk Factors, Epidemiology, G8 Dementia Summit Declaration, Genetics, Global Action Against Dementia, Global Context, Global Leadership, Guardian, Guardian (Newspaper), International Dementia Research, International Dementia Research Inventories, JAMA Neurology, Jo Johnson: Universities and Science Minister, Johns Hopkins University, Laboratory for the Research of Neurodegenerative Diseases: University of Leuven, Laboratory of Neurogenetics: National Institute on Aging, Lifestyle Risk Factors, Mayo Clinic Florida, Medical Research Council (MRC), Medical Research Council (UK), Michael Arthur: UCL President and Provost Professor, MRC: Medical Research Council, National Institutes of Health (NIH), National Institutes of Health (US), National Institutes of Health / National Institutes on Aging, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroimaging of Dementia, Neurology, Neuromuscular Diseases Research Section: National Institute on Aging, Neuroscience, Overlapping Risk Factors, Potential Drug Targets, Preclinical Biomarkers and Dementia, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Recruitment of Research Leaders / Rising Stars, Research and Development, Research and Innovation, Research Commitment, Sir John Savill: Chief Executive of the Medical Research Council, UCL DRI Hub, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), United States, University College London (UCL), University of Leuven, US National Institutes of Health, US National Institutes of Health (NIH), USA, VIB (Belgium), VIB-K.U.Leuven | Leave a comment

Earlier Diagnosis of Parkinson’s Disease? (BBC News / Acta Neuropathologica Communications)

Posted on August 21, 2016 by Dementia and Elderly Care News

Summary Recent animal research, using rats, suggests there may be a cheap and non-invasive method of detecting Parkinson’s Disease early – before symptoms develop – by identifying changes in the eye. The same study also offers early evidence for a … Continue reading →

Posted in Animal Studies, BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK | Tagged Acta Neuropathologica Communications, BBC Health News, Belgium, Biomarkers, DARC: Detection of Apoptosing Retinal Cells, Department of Biology: University of Leuven, Department of Surgery and Cancer: Imperial College London, Drug Discovery Programmes, Early Diagnosis, Early Diagnosis of Parkinson’s Disease, Eye Test to Detect Parkinson's Disease, Faculty of Medicine: Imperial College London, HEYEX® Thickness Map Analysis (Heidelberg Engineering), Imperial College Healthcare NHS Trust, Imperial College London, Imperial College Ophthalmology Research Group (ICORG): Imperial College London, Liposomal Formulation of PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma) Agonist Rosiglitazone, Liposome-Encapsulated Rosiglitazone, Loss of Dopaminergic Neurons in pars compacta of Substantia Nigra (SNpc), Neural Circuit Development and Regeneration Research Group: University of Leuven, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroprotective Agents, Neuroprotective Effect of Rosiglitazone, Nigrostriatal Neurons, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Parkinson’s UK, Preclinical Biomarkers in Parkinson's Disease, Rats, Retina as Early Biomarker of Neurodegeneration, Retinal Assessments Using DARC (Detection of Apoptosing Retinal Cells), Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Parkinson's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Parkinson's Disease, Retinal Thickness, Rosiglitazone, Rotenone-Induced Model of Parkinson's Disease, School of Pharmacy: University of London, Substantia Nigra, Surrogate Biomarkers of Neurodegeneration, UCL Institute of Ophthalmology: University College London, University College London (UCL), University of Leuven, Western Eye Hospital: Imperial College Healthcare NHS Trust | Leave a comment

Faintest Hints of Promise From a Recent Dementia Drug Trial? (BBC News / Alzheimer’s Association International Conference)

Posted on July 28, 2016 by Dementia and Elderly Care News

Summary Data from a recent trial involving 891 patients, presented at the Alzheimer’s Association International Conference in Toronto this week, indicates that an experimental new drug (LMTX) appears to slow the death of brain cells and preserve mental function in … Continue reading →

Posted in Alzheimer’s Disease International (ADI), BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Abnormal Proteins (Tau), Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging (Douglas Mental Health University Institute), Alzheimer's Disease Research Unit: McGill University (Canada), Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, BBC Health News, Degenerative Tauopathy, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Douglas Mental Health University Institute: McGill University Research Centre for Studies in Aging, Dr Serge Gauthier: Director of Alzheimer's Disease Research Unit at McGill University in Canada, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Global Dementia Research, Leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), Leucomethylthioninium Salts (LMTX), LMTM Monotherapy, LMTX, Ltd., Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Tau, Tau Aggregation, Tau Aggregation Inhibitor Therapy, Tau Aggregation Inhibitors, Tau Pathology, Tau Tangles, Tau-Targeting Drugs, Tauopathy, TauRX, TauRx Therapeutics, Treatment and Prevention of Dementia | Leave a comment

Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)

Posted on May 2, 2016 by Dementia and Elderly Care News

Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute | Leave a comment

Tag Archives: Drug Discovery Programmes

A Further Set-Back for Progress in Dementia Drug Development? (BBC News)

Research Towards a World Without Dementia: Marking World Alzheimer’s Day / World Alzheimer’s Month 2017 (Alzheimer’s Disease International / Department of Health)

Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)

Future Director of the UK Dementia Research Institute (MRC / Guardian / JAMA Neurology)

Earlier Diagnosis of Parkinson’s Disease? (BBC News / Acta Neuropathologica Communications)

Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites